A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Biostatistics Core Facility

Biostatistics Core Facility
Director: Jeffrey Longmate, Ph.D.
Co-Director: David Smith, Ph.D.

The Biostatistics Core facility is a group of statisticians who collaborate in basic, translational, and clinical research in the Cancer Center. The Core is supported by City of Hope’s NCI-funded Cancer Center Support Grant (CCSG), and its services are available to City of Hope researchers.

”The central requirement for successful collaboration is clear, broad, specific, two-way communication on both scientific issues and research roles.”

-- Moses and Thomas, Chapter 18 in Medical Uses of Statistics, 2nd ed., NEJM Books, 1992

Scientific Issues: Areas of statistical expertise include: clinical trials; clinical epidemiology; genetic epidemiology; gene expression and functional genomics; pharmacokinetic modeling; assays, bioassays, and diagnostics; toxicology; and general statistical methods for data summary, inference and prediction;

Research Roles: Core members can help with study design, grant proposals, clinical protocols, data analysis, and manuscripts.
 
Services
Collaboration is our main activity. The core statisticians generally contribute to the design and analysis of research projects as co-investigators and co-authors. We collaborate in basic, translational, clinical and population-based research.

Consulting is available to advise investigators on statistical issues in research. Consulting generally consists of one or two meetings, and it’s free. This is a good way to explore possible collaboration, or just get statistical questions answered.

Case finding: The core can provide HIPAA-compliant identification of patients with stored tissue samples or other characteristics.

Statistical Computing is provided in conjunction with collaboration.

To access services or to use the facility, please contact usat 626-256-HOPE (4673), ext. 61444 or viaemailto schedule an appointment.
 
Research reported in this publication included work performed in the Biostatistics Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
 

Abstract for Grants

The Biostatistics Core is directed by Dr. Jeffrey Longmate, Director of the Division of Biostatistics, with Dr. David D. Smith serving as Co-Director. The Biostatistics Core draws effort from a large part of the Division of Biostatistics, with the Biostatistics Core enabling their participation in Cancer Center-related pilot projects and proposals, which may later develop into externally funded projects.  The Biostatistics Core is directly involved in Cancer Center research from the inception of a research idea to the publication of results.

Clinical research projects account for the largest portion of core use, but the Biostatistics Core also supports basic and translational research, as well as assisting several other cores.  The Biostatistics Core staff collaborate closely with the Biomedical Informatics core to support data processing and analysis of gene expression microarrays, and the Biostatistics Core works closely with both the Clinical Research Informatics Core and the Clinical Trials Management Core to implement City of Hope-conducted or coordinated clinical protocols.  In addition to these ongoing collaborative efforts, there have been more technically-focused projects in which the Biostatistics Core has supported the other cores in the implementation of technologies that involve statistical measurement issues.  This has recently included the Affymetrix Core, the Clinical Immunobiology Correlative Studies Lab, and the Genotyping Core.
 
Services include:
Collaboration is our main activity.  The core statisticians generally contribute to the design and analysis of research projects as co-investigators and co-authors.   We collaborate in basic, translational, clinical and population-based research.
 
Consulting is available to advise investigators on statistical issues in research.  Consulting generally consists of one or two meetings, and it’s free.  This is a good way to explore possible collaboration, or just get statistical questions answered.
 
Case finding:  The core can provide HIPAA-compliant identification of patients with stored tissue samples or other characteristics.
 
Statistical Computing is provided in conjunction with collaboration.
 
The Division of Biostatistics is located in the Information Sciences Bldg. (Bldg. #171).
 

Using the Facility

The core encourages collaboration, so investigators are free to contact faculty statisticians directly. Investigators can request an introduction or consulting appointment by phone or email:
 
Phone: 626-256-HOPE (4673) Ext. 61444
Email: BiostatisticsCore
 
Investigators are encouraged to consult with a statistician early in their planning.
Any core-clearance forms required by administration should reflect collaborations already in place.

Pricing

An initial consulting appointment is available without charge.
 
Grant proposals should cover the effort of participating core staff.  The minimum effort for salary support on proposals is 5%.  Any smaller effort should be requested as an expense rather than personnel.
 
Clinical research projects without grants (e.g. internal or industry funding) should budget an estimated cost for core staff time.
 
In some circumstances (e.g. preliminary work for a grant proposal, a basic science project with an unanticipated need for statistical data analysis, or a small grant program that explicitly limits the use of funds) the investigator may request effort that is supported by core funds.  Not all requests can be accommodated.   Priority is given to Cancer Center members and grant proposals, with the expectation that future effort will be funded.
 

Contact Us

Jeffrey Longmate, Ph.D.
Director
626-256-HOPE (4673), 62478
jlongmate@coh.org

David Smith, Ph.D.
Co-Director
626-256-HOPE (4673)
dsmith02@coh.org
 
Location
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000
 
Information Sciences Building (#171)
Phone:  626-256-HOPE (4673), Ext. 61444
Fax:  626-471-7106 or 626-301-8802
 

Biostatistics Core Facility Directors

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti
800-888-5323
dgrignetti@coh.org

 

For sponsorships inquiries please contact:

Stefanie Sprester
213-241-7160
ssprester@coh.org

Christine Nassr
213-241-7112
cnassr@coh.org

 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 
NEWS & UPDATES
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...